OptiRTP COO Sharyn Harper has been selected by the U.S. Commercial Service as a member of the New Zealand delegation to the 2026 SelectUSA Investment Summit, taking place May 3–6 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

The SelectUSA Investment Summit is the highest-profile event in the United States dedicated to foreign direct investment, hosted by the International Trade Administration within the U.S. Department of Commerce. The U.S. Commercial Service — operating through the American Embassy in Wellington — evaluated both OptiRTP as a company and Sharyn Harper individually as the delegation representative, accepting her biography and credentials into the official 2026 Australia–New Zealand Delegate Directory. The Summit brings together economic development organisations from all 54 U.S. states and territories, federal agency representatives, investors, and service providers for a week of bilateral meetings and presentations.

OptiRTP’s selection follows a series of U.S. market engagement milestones. The company has been featured by the American Chamber of Commerce New Zealand as “Invest in NZ MedTech Going Global.” CEO Jon Doherty and Founder Bogdan Anich presented OBST to a Utah state delegation led by Governor Spencer J. Cox at an AmCham briefing during Auckland Start-Up Week. OptiRTP is pursuing permanent U.S. commercial operations, including American manufacturing partnerships and a planned 180-patient VA clinical trial for its FDA registered Class I medical device, OBST (Optimum Bio Sound Therapy).

Sharyn Harper will also attend the Washington, DC: Your Global Gateway to Innovation spinoff on May 7, reflecting the relevance of acoustic neuromodulation technology across both health and military force readiness applications.